Literature DB >> 22484077

Mortality and discharge to home after closed brain biopsy: analysis of 3523 cases from the State of California, 2003-2009.

Derek R Johnson1, Brian P O'Neill, Paul A Decker, Matt L Kosel, Giuseppe Lanzino, Julie E Hammack.   

Abstract

OBJECTIVE: Closed (percutaneous) brain biopsy is an important diagnostic procedure. Information on patient outcomes after biopsy come largely from single-institution series or population-based samples that include patients treated during periods that may not reflect current neurosurgical practice. We sought to determine the rates of in-hospital mortality and discharge to home after closed brain biopsy, and predictors of these outcomes by using a large population-based hospital discharge database with near-complete case ascertainment.
METHODS: All closed brain biopsies performed in nonfederal hospitals within the State of California between 2003 and 2009 were identified from a discharge database. Adult patients admitted from home were analyzed; patient-level and hospital-level factors were reviewed for predictors of in-hospital mortality and discharge to home. Logistic regression was used to determine significant predictors of outcome.
RESULTS: During the 7-year period, 3523 hospitalizations, including closed brain biopsy, met our inclusion criteria. Overall in-hospital mortality rate was 3.5%, and 67.2% of hospitalizations were followed by discharge directly to home. Scheduled versus unscheduled admission and patient race were predictors of mortality in multivariate analysis. Patient age, hospital biopsy volume, scheduled versus unscheduled admission, and patient race were predictors of discharge to home.
CONCLUSIONS: Closed brain biopsy is associated with a greater rate of mortality than is generally recognized. Most patients are able to return to home directly after biopsy, but the rate of discharge to home is lower at hospitals with lower procedure volumes.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22484077     DOI: 10.1016/j.wneu.2012.03.033

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  5 in total

1.  Readmission risk of malignant brain tumor patients undergoing laser interstitial thermal therapy (LITT) and stereotactic needle biopsy (SNB): a covariate balancing weights analysis of the National Readmissions Database (NRD).

Authors:  Truong H Do; Madeleine A Howard; Elise F Palzer; Jared D Huling; Mohammed A Alvi; Samuel W Cramer; Ping Zhu; Reid A Johnson; James Jean; Jinci Lu; Alec B Jonason; Jacob Hanson; Luke Sabal; Kevin W Sun; Robert A McGovern; Clark C Chen
Journal:  J Neurooncol       Date:  2022-07-23       Impact factor: 4.506

2.  Endoscopic versus stereotactic biopsies of intracranial lesions involving the ventricles.

Authors:  Marcin Birski; Jacek Furtak; Kamil Krystkiewicz; Julita Birska; Karolina Zielinska; Paweł Sokal; Marcin Rusinek; Dariusz Paczkowski; Lukasz Szylberg; Marek Harat
Journal:  Neurosurg Rev       Date:  2020-08-21       Impact factor: 3.042

Review 3.  Liquid Biomarkers for Improved Diagnosis and Classification of CNS Tumors.

Authors:  Severa Bunda; Jeffrey A Zuccato; Mathew R Voisin; Justin Z Wang; Farshad Nassiri; Vikas Patil; Sheila Mansouri; Gelareh Zadeh
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 5.923

4.  Orally Administered 5-aminolevulinic Acid for Isolation and Characterization of Circulating Tumor-Derived Extracellular Vesicles in Glioblastoma Patients.

Authors:  Sybren L N Maas; Thomas S van Solinge; Rosalie Schnoor; Anudeep Yekula; Joeky T Senders; Jeroen de Vrij; Pierre Robe; Bob S Carter; Leonora Balaj; Ger J A Arkesteijn; Esther N M Nolte-'t Hoen; Marike L D Broekman
Journal:  Cancers (Basel)       Date:  2020-11-07       Impact factor: 6.639

Review 5.  High-dimensional investigation of the cerebrospinal fluid to explore and monitor CNS immune responses.

Authors:  Michael Heming; Anna-Lena Börsch; Heinz Wiendl; Gerd Meyer Zu Hörste
Journal:  Genome Med       Date:  2022-08-17       Impact factor: 15.266

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.